Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Reblozyl
Pharma
Bristol Myers' clinical woes deepen with failed Reblozyl ph. 3
With the Reblozyl flop, all four of the pivotal trials that have read out this year for BMS’ currently marketed drugs have turned up negative.
Angus Liu
Jul 18, 2025 11:28am
CEO says BMS can handle impact of IRA price negotiation
Jul 26, 2024 11:36am
BMS rolls out 10-year drug access plan in lower-income countries
May 22, 2024 10:20am
BMS has a plan to reinvigorate recent drug launches
Oct 26, 2023 11:45am
BMS aims for staggering 25 label expansions in the coming years
Sep 15, 2023 12:04pm
BMS' Reblozyl, chasing $4B sales target, wins key FDA expansion
Aug 29, 2023 11:23am
